Definium Therapeutics, Inc 8-K, filed Mar 25, 2022
Definium Therapeutics, Inc. (DFTX)
About this 8-K
Definium Therapeutics, Inc filed this 8-K on March 25, 2022, reporting on events of March 24, 2022.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Determination Not to stand for Re-Election at 2022 Annual Meeting - Sarah Y. Vinson as Director
On March 24, 2022, Sarah Y. Vinson, M.D. notified the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”) that she will not stand for re-election as a director of the Company at its 2022 Annual Meeting and that she will serve her current term until immediately prior to the 2022 Annual Meeting. In her notice to the Company, Dr. Vinson indicated that her decision was not the result of any disagreement with the Company, its management, or the Board.
On March 24, 2022, the Board adopted a resolution to reduce the size of the Board from six members to five members effective as of the date of the 2022 Annual Meeting.
Separation - David D. Guebert as Chief Financial Officer
On March 25, 2022, David D. Guebert and the Company agreed to a separation from the Company with Mr. Guebert’s last day of employment on March 31, 2022. The separation was not related to any disagreements with the Company on any matter relating to its operations, policies, practices or any issues regarding financial disclosures, accounting or legal matters.
A copy of the press release announcing Mr. Guebert’s separation is attached hereto as Exhibit 99.1 and is incorporated into this Item 5.02 by reference.
Named Executive Officer Compensation
On March 24, 2022, the Board, following a review of the Company’s executive compensation program by its Compensation Committee and recommendations, approved certain increases to the base salaries effective April 1, 2022, the payment of cash bonuses for fiscal year 2021 and certain equity awards for certain named executive officers as follows:
| Name and Principal Position | Fiscal Year 2021 Cash Bonus Award ($) |
Fiscal Year 2021 Other Payments |
Fiscal Year 2022 Annual Base Salary ($)(1) |
Fiscal Year 2022 Options |
Fiscal Year 2022 Restricted Stock Units |
|||||||||||||||
| Robert Barrow Chief Executive Officer |
$ | 233,411 | $ | 154,082 | (2) | $ | 565,000 | 2,910,000 | (3) | 1,820,000 | (3) | |||||||||
| Miri Halperin Wernli Executive President |
$ | 175,000 | $ | 50,000 | $ | 390,000 | 780,000 | (3) | 600,000 | (3) | ||||||||||
| Dr. Daniel R. Karlin Chief Medical Officer |
$ | 175,000 | $ | 75,000 | $ | 425,000 | 1,250,000 | (3) | 950,000 | (3) | ||||||||||
| Cynthia Hu Chief Legal Officer, Secretary |
$ | 10,400 | — | $ | 390,000 | 1,560,000 | (4) | 1,200,000 | (4) | |||||||||||
| (1) | Adjustments to the executive officers’ base salaries are effective as of April 1, 2022. |
| (2) | Represents the additional amount that Mr. Barrow would have been paid in 2021 if his base salary was $565,000 beginning June 9,2021, in accordance with Mr. Barrow’s previously approved CEO offer letter. |
| (3) | Vesting monthly over 48 months from the vesting commencement date. |
| (4) | Vesting 25% on the 1st anniversary of employment then 1/48th monthly thereafter for 36 months. |
2022 Incentive Bonus Program Information
Additionally, the Board approved the Company’s 2022 cash bonus targets. Target performance bonus percentages for fiscal year 2022 for the Company’s named executive officers are set forth below and expressed as a percentage of the corresponding 2022 annual base salary.
| Name |
2022 Target Bonus Percentage |
|||
| Robert Barrow Chief Executive Officer |
50 | % | ||
| Miri Halperin Wernli Executive President |
40 | % | ||
| Dr. Daniel R. Karlin Chief Medical Officer |
40 | % | ||
| Cynthia Hu Chief Legal Officer, Secretary |
40 | % | ||
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Press Release, dated March 25, 2022 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MIND MEDICINE (MINDMED) INC. | ||||||
| Date: March 25, 2022 | By: | /s/ Cynthia Hu | ||||
| Name: | Cynthia Hu | |||||
| Title: | Chief Legal Officer & Secretary | |||||
Exhibit 99.1
MindMed Announces Transition of CFO
NEW YORK, March 25, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Chief Financial Officer, David Guebert, will be retiring from his position on March 31, 2022.
“On behalf of the Board of Directors and Executive team, I would like to thank Dave, who was essential to the founding and early growth of our organization,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “As we advance our robust drug development and digital medicine programs, we continue to identify leaders who will guide MindMed through this critical stage in our growth. Dave leaves us well positioned financially and strategically to create long-term value for shareholders and to deliver on our commitment to patients in need of novel treatment options.”
MindMed has retained an executive search firm to assist the Company’s Board of Directors in identifying a new Chief Financial Officer with expertise and experience in the US biotech market.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co